贝伐珠单抗联合培美曲塞/顺铂方案治疗晚期非鳞非小细胞肺癌的疗效  

作　　者：丁玲玉 江哲龙 莫丽钦 刘雅娟[1] 张珍[1] 潘月龙[1] 

机构地区：[1]杭州市肿瘤医院,310008 [2]杭州市第一人民医院,310006

出　　处：《浙江临床医学》2023年第1期100-101,共2页Zhejiang Clinical Medical Journal

摘　　要：目的探讨贝伐珠单抗联合培美曲塞/顺铂方案治疗晚期非鳞非小细胞肺癌(NSCLC)的疗效。方法回顾性分析培美曲塞联合顺铂方案耐药后加用贝伐珠单抗合在晚期非鳞NSCLC中的疗效。结果共纳入21例患者,培美曲塞联合顺铂方案耐药后,加用贝伐珠单抗治疗客观有效率(ORR)为26.3%,中位无疾病进展时间(PFS)为5.2个月(95%CI 3.7~7.5),中位总生存时间(OS)11.5个月(95%CI 7.7~14)。不良反应大部分为轻度。结论在晚期非鳞NSCLC中,培美曲塞/顺铂治疗耐药后保留原方案基础上联合贝伐珠单抗获得较满意的疗效。需要设计前瞻性的临床研究以进一步明确该治疗方案的疗效。Objective To explore the efficacy of bevacizumab combined with pemetrexed/cisplatin regimen in the treatment of advanced non-squamous non-small cell lung cancer(NSCLC).Methods Retrospectively analyze the efficacy of pemetrexed,cisplatin,and bevacizumab in advanced non-squamous NSCLC previously treated with pemetrexed and cisplatin.Results A total of 21 patients were included.After the pemetrexed combined with cisplatin regimen was resistant,the objective response rate(ORR)of adding novel regimen was 26.3%,median progression-free survival(PFS)was 5.2 months(95%CI:3.7 to 7.5 months)and median overall survival(OS)was 11.5 months(95%CI:7.7 to 14 months).Adverse events were similar to historic data,and generally mild.Conclusion The combination of pemetrexed,cisplatin and bevacizumab obtains promising results in pemetrexed/cisplatin-refractory metastatic non-squamous NSCLC.Prospective clinical trials are needed to further investigate the efficacy of this regimen.

关 键 词：非小细胞肺癌 贝伐珠单抗 耐药 

分 类 号：R73[医药卫生—肿瘤]